As of 2024-12-11, the Intrinsic Value of Aeglea Bio Therapeutics Inc (AGLE) is
-363.49 USD. This AGLE valuation is based on the model Peter Lynch Fair Value.
With the current market price of 12.01 USD, the upside of Aeglea Bio Therapeutics Inc is
-3,126.59%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
-363.49 USD
Intrinsic Value
AGLE Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| Fair Value |
-363.49 - -363.49 |
-363.49 |
-3,126.59% |
| P/E |
(1,323.12) - (1,423.44) |
(1,355.83) |
-11389.2% |
| DDM - Stable |
(425.85) - (1,325.25) |
(875.55) |
-7390.2% |
| DDM - Multi |
(107.50) - (270.03) |
(154.87) |
-1389.5% |
AGLE Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
48.64 |
| Beta |
0.13 |
| Outstanding shares (mil) |
4.05 |
| Enterprise Value (mil) |
-41.96 |
| Market risk premium |
5.00% |
| Cost of Equity |
12.44% |
| Cost of Debt |
5.00% |
| WACC |
8.06% |